iso-propyl 2-cyano-4,4-dimethyl-6-[3-(trifluoromethyl)benzoyl]-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-8-carboxylate | 1158716-11-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - Pyrroloazepines
• 英文名称: iso-propyl 2-cyano-4,4-dimethyl-6-[3-(trifluoromethyl)benzoyl]-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-8-carboxylate
• 英文别名: Isopropyl 2-cyano-4,4-dimethyl-6-[3-(trifluoromethyl)benzoyl]-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-8-carboxylate；Isopropyl 2-cyano-4,4-dimethyl-6-(3-(trifluoromethyl)benzoyl)-1,4,5,6-tetrahydropyrrolo[3,2-d]azepine-8-carboxylate；propan-2-yl 2-cyano-4,4-dimethyl-6-[3-(trifluoromethyl)benzoyl]-1,5-dihydropyrrolo[2,3-d]azepine-8-carboxylate
• CAS: 1158716-11-0
• 化学式: C₂₃H₂₂F₃N₃O₃
• 分子量: 445.441
• InChiKey: HEEVZNKQDQTZBT-UHFFFAOYSA-N

物化性质

• 沸点：
  585.2±50.0 °C(predicted)
• 密度：
  1.34±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  86.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  iso-propyl 2-cyano-4,4-dimethyl-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-8-carboxylate 、 3-(三氟甲基)苯甲酰氯 生成 iso-propyl 2-cyano-4,4-dimethyl-6-[3-(trifluoromethyl)benzoyl]-1,4,5,6-tetrahydropyrrolo[2,3-d]azepine-8-carboxylate
  参考文献：
  名称：

  1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY

  摘要：

  本文披露了化学实体，包括公式I的化合物及其药物可接受的盐，其中X选择自CN，CF3，CF2H，S（O）nR8和S（O）2N（R9）R10; Y选择自CR11和N; Z选择自O和NH; R3选择自—C（O）R12和—C（O）N（R9）R10; n，R1，R2和R4-R12在此定义; 包含一个或多个这样的化学实体的组合物; 以及使用一个或多个这样的化学实体调节某些受体（例如，法尼索德X）的活性或治疗或预防与这些受体的活性相关的一种或多种疾病或症状的方法。

  公开号：

  US20090137554A1

文献信息

• Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR)
  作者：John F. Mehlmann、Matthew L. Crawley、Joseph T. Lundquist、Ray J. Unwalla、Douglas C. Harnish、Mark J. Evans、Callain Y. Kim、Jay E. Wrobel、Paige E. Mahaney

  DOI：10.1016/j.bmcl.2009.07.148

  日期：2009.9

  Pyrrole[2,3-d]azepines have been identified as potent agonists of the farnesoid X receptor (FXR). Based on the planar X-ray crystal structure of WAY-362450 1 in the ligand binding domain and molecular modeling studies, non-planar reduced compounds were designed which led to agonists that exhibit high aqueous solubility and retain moderate in vitro potency. (C) 2009 Elsevier Ltd. All rights reserved.